NASDAQ · STOCK
West Pharmaceutical Services
$337.55
52W $223.83 – $386.00
60/100
—
42.8
1.16
Is WST Bullish or Bearish?
Bullish.
Innellis AI committee rates West Pharmaceutical Services (WST) Buy with a composite score of 60/100
, based on 7 analysts with 43% agreement.
Last updated July 29, 2026.
What Would Change This View
- Upgrade to Strong Buy
- Requires a committee score of 75.0 — +15.22 from today. Applies on the first day at or above the line; upgrades are never dampened.
- Downgrade to Watch
- Requires the score to fall below 55.0 — -4.78 from today. The band boundary is 60.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.
Executive Summary
The committee is genuinely divided. Risk Analyst sees a compelling case — low leverage (debt-to-equity 0.07) -- balance sheet can absorb a shock. Technical Analyst remains cautious — rsi at 28 is in oversold territory (could mean either capitulation or a bounce setup). This disagreement is itself the signal — the setup is not clean in either direction.
Bull & Bear Case
Bull Case
- ROE of 18.5% shows genuine earnings power backing the valuation — Value
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Low leverage (debt-to-equity 0.07) -- balance sheet can absorb a shock — Risk
- Market regime is bullish (Bull market -- normal position sizing) — Macro
Bear Case
- P/E of 42.1 is expensive by classic value standards — Value
- Price-to-book of 6.2x prices in significant intangible value — Value
- RSI at 28 is in oversold territory (could mean either capitulation or a bounce setup) — Technical
- MACD histogram negative -- bearish momentum — Technical
- Price trading below the lower Bollinger Band -- stretched to the downside — Technical
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of July 29, 2026
Overall Committee Score
60/100
Agreement
43%
Analysts
7
Conviction
Contested
Sector Rank
Top 20%
of 93 Healthcare peers
Value Analyst
neutral
49
/ 100 · High confidence
Fair value -- neither a bargain nor obviously overpriced
+ ROE of 18.5% shows genuine earnings power backing the valuation
− P/E of 42.1 is expensive by classic value standards
Growth Analyst
bullish
77
/ 100 · High confidence
Strong, accelerating growth with consistent execution
+ 5 consecutive earnings beats -- consistent execution
Technical Analyst
bearish
38
/ 100 · High confidence
Price action is deteriorating -- trend and/or momentum are working against this name
− RSI at 28 is in oversold territory (could mean either capitulation or a bounce setup)
Risk Analyst
bullish
80
/ 100 · Low confidence
Risk profile is manageable -- leverage, volatility, and event exposure all look contained
+ Low leverage (debt-to-equity 0.07) -- balance sheet can absorb a shock
Macro Analyst
bullish
70
/ 100 · Moderate confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
+ Market regime is bullish (Bull market -- normal position sizing)
News Analyst
neutral
60
/ 100 · Low confidence
News flow is mixed or quiet -- no strong signal either way right now
Portfolio Manager
neutral
45
/ 100 · High confidence
Portfolio-level factors are mixed -- worth a deliberate sizing decision, not a default-size position
+ Portfolio position concentration is currently healthy
− Sector concentration is already high (HHI 3206.65)
Investment Thesis Evolution
Committee score moved marginally from 59.8 to 59.8.
Comparing 2026-07-28 to 2026-07-29 (1 day apart).
Technical Analysis
RSI (14)
36.8
Neutral
MACD Histogram
-4.426
Bearish Momentum
Trend Direction
Sideways
Weekly: Uptrend
Market Structure
Hh Hl
Bollinger %B
0.08
Inside Bands
Price vs Moving Averages
EMA 9
$345.32
Below
EMA 21
$347.59
Below
EMA 50
$335.19
Above
EMA 200
$291.13
Above
Fundamental Analysis
Valuation
8
Growth
89
Profitability
1
Financial Health
100
Cash Flow
37
Valuation
P/E Ratio
42.8×
P/B Ratio
7.98×
PEG Ratio
2.50
Dividend Yield
0.00%
52W High
$386.00
52W Low
$223.83
Quality & Growth
ROE
15.5%
ROA
11.6%
Gross Margin
36.8%
Operating Margin
20.6%
Revenue Growth YoY
—
Debt / Equity
0.10
AI Fundamental Assessment
P/E ratio of 42.8 (rich relative to a 15-40x range); Price-to-book of 8.0x; PEG ratio of 2.5 (under 1.0 suggests growth is undervalued relative to price); Return on equity of 0.2%; Return on assets of 0.1%; Net margin of 0.2%; Gross margin of 0.4%; Current ratio of 2.82 (healthy short-term liquidity); Debt-to-equity of 0.10; Free cash flow margin of 0.7% (thin cash generation); Free cash flow per share is positive (6.17); Most recent quarter beat estimates by 12.8%; 5 consecutive earnings beats; EPS growth accelerating (+4.4% -> +11.3% QoQ); Average YoY EPS growth of 28.8%; Analyst estimates rising over recent quarters
Get the Full WST Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →